Could a stem cell transplant tame tough scleroderma?
NCT ID NCT03630211
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study tests a stem cell transplant using the patient's own blood cells to treat severe scleroderma (systemic sclerosis) that hasn't improved with standard drugs. The goal is to see if this high-dose therapy is safe and can stop the disease from getting worse. The trial enrolls 8 people aged 8 to 24 with treatment-resistant scleroderma.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE SCLEROSIS SYSTEMIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Pittsburgh of UPMC
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15261, United States
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15261, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scoliosis's hidden toll: can we predict lung and heart risks?
- Can AI catch lung scarring that doctors might miss?
- Which breathing setting keeps Kids' lungs healthier during heart surgery?
- Could a simple sleep guide ease insomnia in lung disease?
- Can arm workouts boost oxygen use in lung disease?
- A Needle-Free heart check? MRI may replace invasive catheterization